TD Asset Management Inc Has $8.36 Million Stock Holdings in Soleno Therapeutics, Inc. $SLNO

TD Asset Management Inc boosted its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 34.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 99,810 shares of the company’s stock after purchasing an additional 25,800 shares during the period. TD Asset Management Inc owned 0.20% of Soleno Therapeutics worth $8,362,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of SLNO. GAMMA Investing LLC boosted its position in Soleno Therapeutics by 4,377.3% during the first quarter. GAMMA Investing LLC now owns 3,358 shares of the company’s stock valued at $240,000 after purchasing an additional 3,283 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Soleno Therapeutics by 8.6% in the first quarter. SG Americas Securities LLC now owns 4,397 shares of the company’s stock valued at $314,000 after buying an additional 350 shares during the last quarter. Avior Wealth Management LLC lifted its position in shares of Soleno Therapeutics by 72.8% in the first quarter. Avior Wealth Management LLC now owns 3,410 shares of the company’s stock valued at $244,000 after buying an additional 1,437 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of Soleno Therapeutics in the first quarter valued at approximately $232,000. Finally, Lisanti Capital Growth LLC acquired a new stake in shares of Soleno Therapeutics in the first quarter valued at approximately $1,812,000. 97.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. The Goldman Sachs Group set a $125.00 price objective on Soleno Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 7th. Robert W. Baird set a $121.00 price objective on Soleno Therapeutics and gave the company an “outperform” rating in a research report on Friday, July 11th. Oppenheimer raised their price objective on Soleno Therapeutics from $105.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, August 7th. Cowen reaffirmed a “buy” rating on shares of Soleno Therapeutics in a research report on Thursday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price objective (up from $100.00) on shares of Soleno Therapeutics in a research report on Monday, August 18th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $115.92.

Soleno Therapeutics Stock Performance

NASDAQ:SLNO opened at $65.47 on Monday. The stock has a market cap of $3.48 billion, a P/E ratio of -15.81 and a beta of -2.75. The stock has a 50 day simple moving average of $65.18 and a 200 day simple moving average of $73.38. The company has a current ratio of 15.13, a quick ratio of 15.01 and a debt-to-equity ratio of 0.21. Soleno Therapeutics, Inc. has a 1-year low of $41.50 and a 1-year high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.44. The firm had revenue of $32.66 million for the quarter, compared to analyst estimates of $3.91 million. Research analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.